News

The efficacy of diflunisal for the treatment of hereditary transthyretin amyloidosis (ATTR) was confirmed by data from the Swedish ATTR registry, according to…

An echocardiographic scoring model showed high diagnostic performance for transthyretin-mediated cardiac amyloidosis (ATTR-CM), according to a study recently…

Austin, United States, July 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in…

Job Position PurposeAct as the Amyloidosis team lead and line manager, leading a team of MAS. Shape the local strategy and ensure the delivery of scientific-medical…

AbstractIntroduction: Cardiac amyloidosis (CA), including transthyretin (ATTR) and light-chain (AL) subtypes, is an underrecognized mimic of heart failure with…

Long-term treatment with Amvuttra (vutrisiran) was found to be safe and to sustain disease stability in people with hereditary transthyretin amyloidosis with…

Long-term treatment with Amvuttra (vutrisiran) was found to be safe and to sustain disease stability in people with hereditary transthyretin amyloidosis with…

The Transthyretin Amyloidosis Treatment Market is Segmented by Therapy (Targeted Therapy, Supportive Therapy, Pipeline Therapy), Type (ATTR with Polyneuropathy (…

AbstractBACKGROUND:Acoramidis achieves near-complete (≥90%) transthyretin stabilization and is approved to reduce cardiovascular-related hospitalization in…

Study OverviewBrief SummaryAL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be…